Cargando…

Clinical relevance of Paliperidone Palmitate three-month intramuscular injection formulation: an Italian Real-World, Retrospective, one-year Mirror Image Study

INTRODUCTION: Paliperidone Palmitate 3-month (PP3M) formulation, introduced in Italy since 2017, is an effective and safety therapeutic option for patients with schizophrenia, clinically stable with 1-month formulation (PP1M). Only a few “Real World” studies investigated the clinical relevance of PP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vanzetto, S., Cirnigliaro, G., Battini, V., Piccoli, E., Vismara, M., Viganò, C., Dell’Osso, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566695/ http://dx.doi.org/10.1192/j.eurpsy.2022.879

Ejemplares similares

Incidence and predictive factors of non adherence to therapy in young adults attending a psycho social center in Milan: a retrospective observational “Real world” study
por: Vanzetto, S., et al.
Publicado: (2022)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

Peripheral Biomarkers in DSM-5 Anxiety Disorders: An Updated Overview
por: Vismara, Matteo, et al.
Publicado: (2020)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash, Abigail I, et al.
Publicado: (2019)

Structured Evaluation of Rehabilitation Programs Outcomes in Psychiatry: Application of a Recovery-Centered Model
por: Vanzetto, Simone, et al.
Publicado: (2021)

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions. 60 months of follow-up
por: Romero Guillena, S.L., et al.
Publicado: (2022)

PALIPERIDONE PALMITATE 6-MONTH FORMULATION FOR THE TREATMENT OF SCHIZOPHRENIA: A 4-MONTH FOLLOW-UP STUDY
por: Romero Guillena, S. L., et al.
Publicado: (2023)

Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia
por: Shimizu, Hiroko, et al.
Publicado: (2019)

Mental health evaluation of patients with Inflammatory Bowel Disease and psychiatric comorbidities during the COVID-19 pandemic
por: Vanzetto, S., et al.
Publicado: (2022)

Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
por: Alphs, Larry, et al.
Publicado: (2011)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2023)

PM531. Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population
por: Russu, Alberto, et al.
Publicado: (2016)

The Impact of Paliperidone Palmitate on Hospitalization in Patients with Schizophrenia: A Retrospective Mirror-image Study
por: Oh, So-Young, et al.
Publicado: (2019)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

Predictors of transition from paliperidone palmitate 1 and 3 months (PP1M & PPP3M) to paliperidone palmitate 6 months (PP6M)
por: Escobedo-Aedo, P. J., et al.
Publicado: (2023)

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions and emergency room visits. 66 months of follow-up
por: Romero Guillena, S. L., et al.
Publicado: (2023)

Alternative initiations with 6-monthly paliperidone palmitate. A descriptive study
por: Sobrino, O. C., et al.
Publicado: (2023)

Alternative initiations with 6-monthly paliperidone palmitate. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
por: Cicala, Giuseppe, et al.
Publicado: (2023)

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?
por: Ravenstijn, Paulien, et al.
Publicado: (2016)

One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives
por: Spoelstra, S Kor, et al.
Publicado: (2022)

Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
por: Bell Lynum, Karimah S., et al.
Publicado: (2018)

Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
por: Pai, Nagesh, et al.
Publicado: (2018)

Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder
por: Fu, Dong-Jing, et al.
Publicado: (2016)

Different onset patterns of monthly paliperidone palmitate in hospitalised patient diagnosed with schizophrenia
por: Herrera-Sánchez, Javier, et al.
Publicado: (2021)

Comparison of Paliperidone Palmitate from Different Crystallization Processes and Effect on Formulations In Vitro and In Vivo
por: Shi, Junfeng, et al.
Publicado: (2022)

The impact of COVID-19 on the psychiatric emergency departments of two Italian hospitals in Milan
por: Cafaro, Rita, et al.
Publicado: (2022)

Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study
por: Bioque, Miquel, et al.
Publicado: (2020)

Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
por: Fernández-Miranda, Juan J., et al.
Publicado: (2021)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
por: O’Donnell, Amy, et al.
Publicado: (2021)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
por: Savitz, Adam J, et al.
Publicado: (2019)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
por: Savitz, Adam J., et al.
Publicado: (2016)

Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia
por: Garcia-Portilla, Maria Paz, et al.
Publicado: (2020)

Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study
por: Pappa, Sofia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kt2fhpoo370tqd3jjk6mrohh27